1
|
Aristei C, Kaidar-Person O, Boersma L, Leonardi MC, Offersen B, Franco P, Arenas M, Bourgier C, Pfeffer R, Kouloulias V, Bölükbaşı Y, Meattini I, Coles C, Luis AM, Masiello V, Palumbo I, Morganti AG, Perrucci E, Tombolini V, Krengli M, Marazzi F, Trigo L, Borghesi S, Ciabattoni A, Ratoša I, Valentini V, Poortmans P. The 2022 Assisi Think Tank Meeting: White paper on optimising radiation therapy for breast cancer. Crit Rev Oncol Hematol 2023:104035. [PMID: 37244324 DOI: 10.1016/j.critrevonc.2023.104035] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2023] [Revised: 05/11/2023] [Accepted: 05/23/2023] [Indexed: 05/29/2023] Open
Abstract
The present white paper, referring to the 4th Assisi Think Tank Meeting on breast cancer, reviews state-of-the-art data, on-going studies and research proposals. < 70% agreement in an online questionnaire identified the following clinical challenges: 1: Nodal RT in patients who have a) 1-2 positive sentinel nodes without ALND (axillary lymph node dissection); b) cN1 disease transformed into ypN0 by primary systemic therapy and c) 1-3 positive nodes after mastectomy and ALND. 2. The optimal combination of RT and immunotherapy (IT), patient selection, IT-RT timing, and RT optimal dose, fractionation and target volume. Most experts agreed that RT- IT combination does not enhance toxicity. 3: Re-irradiation for local relapse converged on the use of partial breast irradiation after second breast conserving surgery. Hyperthermia aroused support but is not widely available. Further studies are required to finetune best practice, especially given the increasing use of re-irradiation.
Collapse
Affiliation(s)
- C Aristei
- Radiation Oncology Section, Department of Medicine and Surgery, University of Perugia and Perugia General Hospital, Perugia, Italy.
| | - O Kaidar-Person
- Breast Radiation Unit, Radiation Oncology, Sheba Medical Center, Ramat Gan, Israel
| | - L Boersma
- Radiation Oncology (Maastro), GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, the Netherlands
| | - M C Leonardi
- Division of Radiation Oncology, IEO European Institute of Oncology, IRCCS, Milan, Italy
| | - B Offersen
- Department of Experimental Clinical Oncology, Department of Oncology, Danish Centre for Particle Therapy, Aarhus University Hospital, Aarhus, Denmark
| | - P Franco
- Depatment of Translational Medicine, University of Eastern Piedmont and Department of Radiation Oncology, 'Maggiore della Carita`' University Hospital, Novara, Italy
| | - M Arenas
- Universitat Rovira I Virgili, Radiation Oncology Department, Hospital Universitari Sant Hoan de Reus, IISPV, Spain
| | - C Bourgier
- Radiation Oncology, ICM-Val d' Aurelle, Univ Montpellier, Montpellier, France
| | - R Pfeffer
- Oncology Institute, Assuta Medical Center, Tel Aviv and Ben Gurion University Medical School, Israel
| | - V Kouloulias
- 2nd Department of Radiology, Radiotherapy Unit, Medical School, National and Kapodistrian University of Athens, Greece
| | - Y Bölükbaşı
- Koc University, Faculty of Medicine, Department of Radiation Oncology, Istanbul, Turkey
| | - I Meattini
- Department of Experimental and Clinical Biomedical Sciences "M. Serio", University of Florence & Radiation Oncology Unit - Oncology Department, Azienda Ospedaliero Universitaria Careggi, Florence, Italy
| | - C Coles
- Department of Oncology, University of Cambridge, UK
| | - A Montero Luis
- Department of Radiation Oncology, University Hospital HM Sanchinarro, HM Hospitales, Madrid, Spain
| | - V Masiello
- Unità Operativa di Radioterapia Oncologica, Dipartimento di Diagnostica per Immagine, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Gemelli IRCSS Roma, Italy
| | - I Palumbo
- Radiation Oncology Section, Department of Medicine and Surgery, University of Perugia and Perugia General Hospital, Perugia, Italy
| | - A G Morganti
- DIMES, Alma Mater Studiorum Bologna University, Bologna, Italy; Radiation Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Alma Mater Studiorum Bologna University; Bologna, Italy
| | - E Perrucci
- Radiation Oncology Section, Perugia General Hospital, Perugia, Italy
| | - V Tombolini
- Radiation Oncology, Department of Radiological, Oncological and Pathological Science, University "La Sapienza", Roma, Italy
| | - M Krengli
- DISCOG, Università di Padova e Istituto Oncologico Veneto - IRCCS
| | - F Marazzi
- Unità Operativa di Radioterapia Oncologica, Dipartimento di Diagnostica per Immagine, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Gemelli IRCSS Roma, Italy
| | - L Trigo
- Service of Brachytherapy, Department of Image and Radioncology, Instituto Português Oncologia Porto Francisco Gentil E.P.E., Portugal
| | - S Borghesi
- Radiation Oncology Unit of Arezzo-Valdarno, Azienda USL Toscana Sud Est, Italy
| | - A Ciabattoni
- Department of Radiation Oncology, San Filippo Neri Hospital, ASL Rome 1, Rome, Italy
| | - I Ratoša
- Division of Radiation Oncology, Institute of Oncology Ljubljana, Ljubljana, Slovenia; Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia
| | - V Valentini
- Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Università Cattolica del Sacro Cuore e Fondazione Policlinico Gemelli IRCSS Roma, Italy
| | - P Poortmans
- Department of Radiation Oncology, Iridium Kankernetwerk, Antwerp, Belgium; University of Antwerp, Faculty of Medicine and Health Sciences, Antwerp, Belgium
| |
Collapse
|
2
|
Chiesa S, Russo R, Beghella Bartoli F, Palumbo I, Sabatino G, Cannatà MC, Gigli R, Longo S, Tran HE, Boldrini L, Dinapoli N, Votta C, Cusumano D, Pignotti F, Lupattelli M, Camilli F, Della Pepa GM, D’Alessandris GQ, Olivi A, Balducci M, Colosimo C, Gambacorta MA, Valentini V, Aristei C, Gaudino S. MRI-derived radiomics to guide post-operative management of glioblastoma: Implication for personalized radiation treatment volume delineation. Front Med (Lausanne) 2023; 10:1059712. [PMID: 36744131 PMCID: PMC9892450 DOI: 10.3389/fmed.2023.1059712] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2022] [Accepted: 01/03/2023] [Indexed: 01/20/2023] Open
Abstract
Background The glioblastoma's bad prognosis is primarily due to intra-tumor heterogeneity, demonstrated from several studies that collected molecular biology, cytogenetic data and more recently radiomic features for a better prognostic stratification. The GLIFA project (GLIoblastoma Feature Analysis) is a multicentric project planned to investigate the role of radiomic analysis in GB management, to verify if radiomic features in the tissue around the resection cavity may guide the radiation target volume delineation. Materials and methods We retrospectively analyze from three centers radiomic features extracted from 90 patients with total or near total resection, who completed the standard adjuvant treatment and for whom we had post-operative images available for features extraction. The Manual segmentation was performed on post gadolinium T1w MRI sequence by 2 radiation oncologists and reviewed by a neuroradiologist, both with at least 10 years of experience. The Regions of interest (ROI) considered for the analysis were: the surgical cavity ± post-surgical residual mass (CTV_cavity); the CTV a margin of 1.5 cm added to CTV_cavity and the volume resulting from subtracting the CTV_cavity from the CTV was defined as CTV_Ring. Radiomic analysis and modeling were conducted in RStudio. Z-score normalization was applied to each radiomic feature. A radiomic model was generated using features extracted from the Ring to perform a binary classification and predict the PFS at 6 months. A 3-fold cross-validation repeated five times was implemented for internal validation of the model. Results Two-hundred and seventy ROIs were contoured. The proposed radiomic model was given by the best fitting logistic regression model, and included the following 3 features: F_cm_merged.contrast, F_cm_merged.info.corr.2, F_rlm_merged.rlnu. A good agreement between model predicted probabilities and observed outcome probabilities was obtained (p-value of 0.49 by Hosmer and Lemeshow statistical test). The ROC curve of the model reported an AUC of 0.78 (95% CI: 0.68-0.88). Conclusion This is the first hypothesis-generating study which applies a radiomic analysis focusing on healthy tissue ring around the surgical cavity on post-operative MRI. This study provides a preliminary model for a decision support tool for a customization of the radiation target volume in GB patients in order to achieve a margin reduction strategy.
Collapse
Affiliation(s)
- S. Chiesa
- Department of Radiology, Radiation Oncology and Hematology, Fondazione Policlinico Universitario “A. Gemelli” IRCCS, Rome, Italy
| | - R. Russo
- Department of Diagnostic Imaging, Oncological Radiotherapy and Hematology, Institute of Radiology, Fondazione Policlinico Universitario “A. Gemelli” IRCCS, Rome, Italy
| | - F. Beghella Bartoli
- Department of Radiology, Radiation Oncology and Hematology, Fondazione Policlinico Universitario “A. Gemelli” IRCCS, Rome, Italy
| | - I. Palumbo
- Radiation Oncology Section, University of Perugia, Perugia, Italy,Perugia General Hospital, Perugia, Italy
| | - G. Sabatino
- Department of Neurosurgery, Mater Olbia Hospital, Olbia, Italy,Department of Neurosurgery, Agostino Gemelli University Polyclinic (IRCCS), Rome, Italy
| | - M. C. Cannatà
- Department of Radiology, Radiation Oncology and Hematology, Fondazione Policlinico Universitario “A. Gemelli” IRCCS, Rome, Italy,*Correspondence: M. C. Cannatà,
| | - R. Gigli
- Medical Physics, Mater Olbia Hospital, Olbia, Italy
| | - S. Longo
- Department of Radiology, Radiation Oncology and Hematology, Fondazione Policlinico Universitario “A. Gemelli” IRCCS, Rome, Italy
| | - H. E. Tran
- Department of Radiology, Radiation Oncology and Hematology, Fondazione Policlinico Universitario “A. Gemelli” IRCCS, Rome, Italy
| | - L. Boldrini
- Department of Radiology, Radiation Oncology and Hematology, Fondazione Policlinico Universitario “A. Gemelli” IRCCS, Rome, Italy
| | - N. Dinapoli
- Department of Radiology, Radiation Oncology and Hematology, Fondazione Policlinico Universitario “A. Gemelli” IRCCS, Rome, Italy
| | - C. Votta
- Department of Radiology, Radiation Oncology and Hematology, Fondazione Policlinico Universitario “A. Gemelli” IRCCS, Rome, Italy
| | - D. Cusumano
- Medical Physics, Mater Olbia Hospital, Olbia, Italy
| | - F. Pignotti
- Department of Neurosurgery, Mater Olbia Hospital, Olbia, Italy,Department of Neurosurgery, Agostino Gemelli University Polyclinic (IRCCS), Rome, Italy
| | | | - F. Camilli
- Radiation Oncology Section, University of Perugia, Perugia, Italy
| | - G. M. Della Pepa
- Department of Neurosurgery, Agostino Gemelli University Polyclinic (IRCCS), Rome, Italy
| | - G. Q. D’Alessandris
- Department of Neurosurgery, Agostino Gemelli University Polyclinic (IRCCS), Rome, Italy
| | - A. Olivi
- Department of Neurosurgery, Agostino Gemelli University Polyclinic (IRCCS), Rome, Italy
| | - M. Balducci
- Department of Radiology, Radiation Oncology and Hematology, Fondazione Policlinico Universitario “A. Gemelli” IRCCS, Rome, Italy
| | - C. Colosimo
- Department of Diagnostic Imaging, Oncological Radiotherapy and Hematology, Institute of Radiology, Fondazione Policlinico Universitario “A. Gemelli” IRCCS, Rome, Italy
| | - M. A. Gambacorta
- Department of Radiology, Radiation Oncology and Hematology, Fondazione Policlinico Universitario “A. Gemelli” IRCCS, Rome, Italy
| | - V. Valentini
- Department of Radiology, Radiation Oncology and Hematology, Fondazione Policlinico Universitario “A. Gemelli” IRCCS, Rome, Italy
| | - C. Aristei
- Radiation Oncology Section, University of Perugia, Perugia, Italy,Perugia General Hospital, Perugia, Italy
| | - S. Gaudino
- Department of Diagnostic Imaging, Oncological Radiotherapy and Hematology, Institute of Radiology, Fondazione Policlinico Universitario “A. Gemelli” IRCCS, Rome, Italy
| |
Collapse
|
3
|
Benziane-Ouaritini N, Zilli T, Ingrosso G, di Staso M, Trippa F, Francolini G, Meyer E, Achard V, Schick U, Cosset J, Martin E, Penna RR, Ferrari V, Giraud N, Pasquier C, Magne N, Anger E, Aristei C, Perrenec T, Gnep K, Pasquier D, Supiot S, Sargos P, Latorzeff I. Salvage Radiotherapy Guided by Functional Imaging for Macroscopic Local Recurrence Following Radical Prostatectomy: A Multicentric Retrospective Study. Int J Radiat Oncol Biol Phys 2022. [DOI: 10.1016/j.ijrobp.2022.07.587] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
4
|
Cannatà M, Russo R, Beghella Bartoli F, Palumbo I, Tran H, Votta C, Lupattelli M, Boldrini L, Dinapoli N, Camilli F, Balducci M, Gambacorta M, Valentini V, Aristei C, Sabatino G, Pignotti F, Gaudino S, Chiesa S. P02.11.B An hypothesis generating study of MRI-Derived Radiomics on tumor and microenvironment tissue heterogeneity to guide post-operative management of glioblastoma: toward personalized radiation treatment volume delineation. Neuro Oncol 2022. [DOI: 10.1093/neuonc/noac174.104] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
The glioblastoma’s bad prognosis is primarily due to intra-tumor heterogeneity, demonstrated from several studies that collected molecular biology, cytogenetic data and more recently radiomic features for a better prognostic stratification.The GLIFA project (GLIoblastoma Feature Analysis) is a multicentric project planned to investigated the role of radiomic analysis in GBM management, to verify if radiomic features in the tissue around the resection cavity which may guide the radiation target volume delineation.
Material and Methods
We retrospectively analyze from three centers radiomic features extracted from 90 patients with total or near total resection, who completed the standard adjuvant treatment and for whom we had post-operative images available for features extraction.The Manual segmentation was performed on post gadolinium T1w MRI sequence by 2 radiation oncologist reviewed by a neuroradiologist, both with at least 10 years of experience. The Region of interest (ROI) considered for the analysis were: the surgical cavity +/- post-surgical residual mass (CTV_cavity); the CTV a margin of 1.5 cm added to CTV_cavity and the volume resulting from subtracting the CTV_cavity from the CTV was defined as CTV_Ring. Radiomic analysis and modelling were conducted in RStudio. Z-score normalization was applied to each radiomic feature. A radiomic model was generated using the 226 features extracted from the Ring to perform a binary classification and predict the PFS at 6 months (statistical, morphological and textural features). A 3-fold cross-validation repeated five times was implemented for internal validation of the model.
Results
Two-hundred and seventy ROIs were contoured. The proposed radiomic model was given by the best fitting logistic regression model, and included the following 3 features: F_cm_merged.contrast, F_cm_merged.info.corr.2, F_rlm_merged.rlnu. A good agreement between model predicted probabilities and observed outcome probabilities was obtained (p-value of 0.49 by Hosmer and Lemeshow statistical test). The ROC curve of the model reported an AUC of 0.78 (95% CI: 0.68 - 0.88).
Conclusion
This is the first hypothesis-generating study who applies a radiomic analysis focusing on healthy tissue ring around the surgical cavity on post-operative MRI. This study provides a preliminary model for a decision support tool for a customization of the radiation target volume in GBM patients in order to achieve a margin reduction strategy.
Collapse
Affiliation(s)
- M Cannatà
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS and Università Cattolica del Sacro Cuore , Roma , Italy
| | - R Russo
- Department of Diagnostic Imaging, Oncological Radiotherapy, and Hematology, UOC Neuroradiology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS and Università Cattolica del Sacro Cuore , Roma , Italy
| | - F Beghella Bartoli
- Department of Diagnostic Imaging, Oncological Radiotherapy, and Hematology, UOC Oncological Radiotherapy, Fondazione Policlinico Universitario Agostino Gemelli IRCCS , Roma , Italy
| | - I Palumbo
- Radiation Oncology Section, General Hospital , Perugia , Italy
| | - H Tran
- Department of Diagnostic Imaging, Oncological Radiotherapy, and Hematology, UOC Oncological Radiotherapy, Fondazione Policlinico Universitario Agostino Gemelli IRCCS , Roma , Italy
| | - C Votta
- Department of Diagnostic Imaging, Oncological Radiotherapy, and Hematology, UOC Oncological Radiotherapy, Fondazione Policlinico Universitario Agostino Gemelli IRCCS , Roma , Italy
| | - M Lupattelli
- Radiation Oncology Section, General Hospital , Perugia , Italy
| | - L Boldrini
- Department of Diagnostic Imaging, Oncological Radiotherapy, and Hematology, UOC Oncological Radiotherapy, Fondazione Policlinico Universitario Agostino Gemelli IRCCS , Roma , Italy
| | - N Dinapoli
- Department of Diagnostic Imaging, Oncological Radiotherapy, and Hematology, UOC Oncological Radiotherapy, Fondazione Policlinico Universitario Agostino Gemelli IRCCS , Roma , Italy
| | - F Camilli
- Radiation Oncology Section, General Hospital , Perugia , Italy
| | - M Balducci
- Department of Diagnostic Imaging, Oncological Radiotherapy, and Hematology, UOC Oncological Radiotherapy, Fondazione Policlinico Universitario Agostino Gemelli IRCCS , Roma , Italy
| | - M Gambacorta
- Department of Diagnostic Imaging, Oncological Radiotherapy, and Hematology, UOC Oncological Radiotherapy, Fondazione Policlinico Universitario Agostino Gemelli IRCCS , Roma , Italy
| | - V Valentini
- Department of Diagnostic Imaging, Oncological Radiotherapy, and Hematology, UOC Oncological Radiotherapy, Fondazione Policlinico Universitario Agostino Gemelli IRCCS , Roma , Italy
| | - C Aristei
- Radiation Oncology Section, General Hospital , Perugia , Italy
| | - G Sabatino
- Radiation Oncology, Mater Olbia Hospital , 07026, Olbia , Italy
| | - F Pignotti
- Department of Neurosurgery, Mater Olbia Hospital , Olbia , Italy
| | - S Gaudino
- Department of Diagnostic Imaging, Oncological Radiotherapy, and Hematology, UOC Neuroradiology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS and Università Cattolica del Sacro Cuore , Roma , Italy
| | - S Chiesa
- Department of Diagnostic Imaging, Oncological Radiotherapy, and Hematology, UOC Oncological Radiotherapy, Fondazione Policlinico Universitario Agostino Gemelli IRCCS , Roma , Italy
| |
Collapse
|
5
|
Chiesa S, Beghella Bartoli F, Mazzarella C, Hohaus S, Cannatà M, Catucci F, D'Alò F, Bracci S, Nardangeli A, Martino A, Dinapoli N, Marazzi F, Manfrida S, Gambacorta M, Aristei C, Valentini V, Balducci M. OC-0929 How to manage consolidative radiotherapy after HD methotrexate in PCNSL patients: a phase II study. Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)02709-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
6
|
Francolini G, Detti B, Becherini C, Caini S, Ingrosso G, Di Cataldo V, Stocchi G, Salvestrini V, Lancia A, Scartoni D, Giacomelli I, Sardaro A, Carbonara R, Borghesi S, Aristei C, Livi L. Toxicity after moderately hypofractionated versus conventionally fractionated prostate radiotherapy: A systematic review and meta-analysis of the current literature. Crit Rev Oncol Hematol 2021; 165:103432. [PMID: 34352361 DOI: 10.1016/j.critrevonc.2021.103432] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2020] [Revised: 07/06/2021] [Accepted: 07/28/2021] [Indexed: 11/30/2022] Open
Abstract
BACKGROUND Moderately hypofractionated radiotherapy (RT) currently represents the standard RT approach for all prostate cancer (PCa) risk categories. We performed a systematic review and meta-analysis of available literature, focusing on acute and late genitourinary (GU) and gastrointestinal (GI) adverse events (AEs) of moderate hypofractionation for localized PCa. MATERIALS AND METHODS Literature search was performed and two independent reviewers selected the records according to the following Population (P) Intervention (I) Comparator (C) and Outcomes (O) (PICO) question: "In patients affected by localized PCa (P), moderately hypofractionated RT (defined as a treatment schedule providing a single dose per fraction of 3-4.5 Gy) (I) can be considered equivalent to conventionally fractionated RT (C) in terms of G > 2 GI and GU acute and late adverse events (O)?". Bias assessment was performed using Cochrane Cochrane Collaboration's Tool for Assessing Risk of Bias. RESULTS Thirteen records were identified and a meta-analysis was performed. Risk of acute GI and GU > 2 adverse events in the moderately hypofractionated arm was increased by 9.8 % (95 %CI 4.8 %-14.7 %; I2 = 57 %) and 1.5 % (95 % CI -1.5 %-4.4 %; I2 = 0%), respectively. DISCUSSION Overall, majority of trials included in our meta-analysis suggested that moderately hypofractionated RT is equivalent, in terms of GI and GU adverse events, to conventional fractionation. Pooled analysis showed a trend to increased GI toxicity after hypofractionated treatment, but this might be related to dose escalation rather than hypofractionation.
Collapse
Affiliation(s)
- G Francolini
- Radiation Oncology Unit, University of Florence, Florence, Italy
| | - B Detti
- Radiation Oncology Unit, University of Florence, Florence, Italy.
| | - C Becherini
- Radiation Oncology Unit, University of Florence, Florence, Italy
| | - S Caini
- Cancer Risk Factors and Lifestyle Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network (ISPRO), Florence, Italy
| | - G Ingrosso
- Radiation Oncology Section, Department of Surgical and Biomedical Science, University of Perugia, Italy
| | | | - G Stocchi
- Radiation Oncology Unit, University of Florence, Florence, Italy
| | - V Salvestrini
- Radiation Oncology Unit, University of Florence, Florence, Italy
| | - A Lancia
- Department of Medical Sciences and Infectious Disease, Radiation Oncology Unit, Fondazione IRCCS, Policlinico San Matteo, Pavia, Italy
| | - D Scartoni
- Proton Treatment Center, Azienda Provinciale Per i Servizi Sanitari, Trento, Italy
| | - I Giacomelli
- Proton Treatment Center, Azienda Provinciale Per i Servizi Sanitari, Trento, Italy
| | - A Sardaro
- Section of Radiology and Radiation Oncology, Interdisciplinary Department of Medicine, University of Bari Aldo Moro, Bari, Italy
| | - R Carbonara
- Radiation Oncology Department, General Regional Hospital F. Miulli, Acquaviva delle Fonti, BA, Italy
| | - S Borghesi
- Radiotherapy Department, Azienda USL Toscana Sud Est, San Donato Hospital, Arezzo, Italy
| | - C Aristei
- Radiation Oncology Section, Department of Surgical and Biomedical Science, University of Perugia, Italy
| | - L Livi
- Radiation Oncology Unit, University of Florence, Florence, Italy
| |
Collapse
|
7
|
Marco L, Trignani M, Ingrosso G, Di Guglielmo F, Centofanti G, Fasciolo D, Bini V, Genovesi D, Aristei C. PO-1071 Hypofractionated stereotactic radiotherapy of brain metastases: a retrospective analysis. Radiother Oncol 2021. [DOI: 10.1016/s0167-8140(21)07522-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
8
|
Saldi S, Panizza B, Massei M, Capolsini I, Fulcheri C, Ingrosso G, Chierchini S, Mariucci C, Perrucci E, Caniglia M, Aristei C. PO-0921: Total Body Irradiation and adoptive immunotherapy in pediatric HLA-haploidentical transplantation. Radiother Oncol 2020. [DOI: 10.1016/s0167-8140(21)00938-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
9
|
Macchia G, Cerrotta A, Deodato F, Pappalardi B, Re A, Santoni R, Campitelli M, Scambia G, Valentini V, Aristei C, Ferrandina G. PO-1116: Cervical cancer patterns of care in italy: a radiation oncology survey of mito and airo gyn groups. Radiother Oncol 2020. [DOI: 10.1016/s0167-8140(21)01133-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
10
|
Marazzi F, Orlandi A, Masiello V, Zinicola T, Moschella F, Chiesa S, Frascino V, Franceschini G, Bria E, Gambacorta M, Masetti R, Aristei C, Tortora G, Valentini V. 285P Radiotherapy benefit in oligoprogressive breast cancer: A retrospective analysis. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.387] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
11
|
Francolini G, Detti B, Bottero M, Zilli T, Lancia A, Bruni A, Borghesi S, Mariotti M, Castellucci P, Fanti S, Filippi AR, Teriaca MA, Maragna V, Aristei C, Mazzeo E, Livi L, Ingrosso G. Detection rate, pattern of relapse and influence on therapeutic decision of PSMA PET/CT in patients affected by biochemical recurrence after radical prostatectomy, a retrospective case series. Clin Transl Oncol 2020; 23:364-371. [PMID: 32602076 DOI: 10.1007/s12094-020-02427-2] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2020] [Accepted: 06/10/2020] [Indexed: 12/24/2022]
Abstract
AIMS 68Ga-Prostate-specific membrane antigen (PSMA) PET/CT is widely used in patients with biochemical recurrence (BCR) after radical prostatectomy. We collected data about patients staged with PSMA PET/CT after BCR (PSA < 1 ng/ml) in four different institutes. Impact of baseline features (Gleason score, risk classification, PSA at recurrence, PSA doubling time and time to recurrence) was explored to understand predictive factors of (PSMA) PET/CT positivity. Impact of restaging on following treatment approaches was reported. RESULTS 92 patients were included. PSMA PET/CT detection rate was 56.5% and low-volume disease (≤ 3 non-visceral lesions) was detected in 52.2% of patients. After positive scan, 13.5% of patients still lies on observation, ADT alone was administered in 30.8% of cases, Stereotactic body RT (SBRT) alone was delivered to 44.2% of patients and 11.5% of patients underwent concomitant SBRT and ADT. Seven patients underwent conventional salvage prostate bed RT. Chi-squared test showed a higher rate of positive PSMA PET/CT for patients with Gleason score > 7 (p = 0.004) and TTR < 29.5 months (p = 0.003). CONCLUSIONS PSMA PET/CT showed a high detection rate. This influenced clinical management in a significant percentage of patients, allowing treatment tailoring on the basis of imaging.
Collapse
Affiliation(s)
- G Francolini
- Radiation Oncology, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Largo G. A. Brambilla 3, 50134, Florence, Italy.
| | - B Detti
- Radiation Oncology, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Largo G. A. Brambilla 3, 50134, Florence, Italy
| | - M Bottero
- Department of Radiation Oncology, Policlinico Tor Vergata, University of Rome, Rome, Italy
| | - T Zilli
- Radiation Oncology Division, Geneva University Hospital, Geneva, Switzerland
| | - A Lancia
- Radiation Oncology Unit, Department of Medical Sciences and Infectious Disease, Fondazione IRCCS Policlinico San Matteo and University of Pavia, Pavia, Italy
| | - A Bruni
- Radiotherapy Unit, University Hospital of Modena, Modena, Italy
| | - S Borghesi
- UOC Radiation Oncology Arezzo-Valdarno, Azienda USL Toscana Sud Est, Arezzo, Italy
| | - M Mariotti
- Radiation Oncology, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Largo G. A. Brambilla 3, 50134, Florence, Italy
| | - P Castellucci
- Department of Nuclear Medicine, Policlinico S. Orsola-Malpighi, Bologna, Italy
| | - S Fanti
- Department of Nuclear Medicine, Policlinico S. Orsola-Malpighi, Bologna, Italy
| | - A R Filippi
- Radiation Oncology Unit, Department of Medical Sciences and Infectious Disease, Fondazione IRCCS Policlinico San Matteo and University of Pavia, Pavia, Italy
| | - M A Teriaca
- Radiation Oncology, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Largo G. A. Brambilla 3, 50134, Florence, Italy
| | - V Maragna
- Radiation Oncology, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Largo G. A. Brambilla 3, 50134, Florence, Italy
| | - C Aristei
- Radiation Oncology Section, Department of Surgical and Biomedical Science, University of Perugia, Perugia, Italy
| | - E Mazzeo
- Radiotherapy Unit, University Hospital of Modena, Modena, Italy
| | - L Livi
- Radiation Oncology, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Largo G. A. Brambilla 3, 50134, Florence, Italy
| | - G Ingrosso
- Radiation Oncology Section, Department of Surgical and Biomedical Science, University of Perugia, Perugia, Italy
| |
Collapse
|
12
|
Coles CE, Aristei C, Bliss J, Boersma L, Brunt AM, Chatterjee S, Hanna G, Jagsi R, Kaidar Person O, Kirby A, Mjaaland I, Meattini I, Luis AM, Marta GN, Offersen B, Poortmans P, Rivera S. International Guidelines on Radiation Therapy for Breast Cancer During the COVID-19 Pandemic. Clin Oncol (R Coll Radiol) 2020; 32:279-281. [PMID: 32241520 PMCID: PMC7270774 DOI: 10.1016/j.clon.2020.03.006] [Citation(s) in RCA: 167] [Impact Index Per Article: 41.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Affiliation(s)
- C E Coles
- Oncology Department, University of Cambridge, UK.
| | - C Aristei
- University of Perugia, Italy; Perugia General Hospital Sant'Andrea delle Fratte, Italy
| | - J Bliss
- The Institute of Cancer Research Clinical Trials and Statistics Unit, London, UK
| | - L Boersma
- Department of Radiation Oncology (Maastro), GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, the Netherlands
| | - A M Brunt
- University Hospitals of North Midlands & Keele University, Stoke-on-Trent, UK
| | | | - G Hanna
- Peter MacCallum Cancer Centre, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Australia
| | - R Jagsi
- Department of Radiation Oncology, Center for Bioethics and Social Sciences in Medicine, University of Michigan, USA
| | - O Kaidar Person
- Breast Radiation Unit, Sheba Tel Ha'shomer, Ramat Gan, Israel
| | - A Kirby
- Royal Marsden NHS Foundation Trust and Institute of Cancer Research, UK
| | - I Mjaaland
- Department of Hematology and Oncology, Stavanger University Hospital, Norway
| | - I Meattini
- Department of Experimental and Clinical Biomedical Sciences, University of Florence, Italy; Radiation Oncology Unit - Oncology Department, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy
| | - A M Luis
- University Hospital HM Sanchinarro, Madrid, Spain
| | - G N Marta
- Department of Radiation Oncology, Hospital Sírio-Libanês, São Paulo, Brazil; Division of Radiation Oncology, Department of Radiology and Oncology, Instituto do Câncer do Estado de São Paulo, Faculdade de Medicina da Universidade de São Paulo, Brazil
| | - B Offersen
- Department of Experimental Clinical Oncology, Aarhus University Hospital, Denmark
| | - P Poortmans
- Paris Sciences et Lettres University, Paris, France
| | - S Rivera
- Department of Radiation Oncology, Gustave Roussy Cancer Campus, Villejuif, France; Molecular Radiotherapy and Innovative Therapeutics, Gustave Roussy Cancer Campus, Université Paris Saclay, Villejuif, France
| |
Collapse
|
13
|
Montero-Luis A, Aristei C, Meattini I, Arenas M, Boersma L, Bourgier C, Coles C, Cutuli B, Falcinelli L, Kaidar-Person O, Leonardi MC, Offersen B, Marazzi F, Rivera S, Tagliaferri L, Tombolini V, Vidali C, Valentini V, Poortmans P. The Assisi Think Tank Meeting Survey of post-mastectomy radiation therapy in ductal carcinoma in situ: Suggestions for routine practice. Crit Rev Oncol Hematol 2019; 138:207-213. [PMID: 31092377 DOI: 10.1016/j.critrevonc.2019.04.016] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2019] [Revised: 04/11/2019] [Accepted: 04/13/2019] [Indexed: 12/17/2022] Open
Abstract
BACKGROUND Risk factors for local recurrence after mastectomy in ductal carcinoma in situ (DCIS) emerged as a grey area during the second "Assisi Think Tank Meeting" (ATTM) on Breast Cancer. AIM To review practice patterns of post-mastectomy radiation therapy (PMRT) in DCIS, identify risk factors for recurrence and select suitable candidates for PMRT. METHODS A questionnaire concerning DCIS management, focusing on PMRT, was distributed online via SurveyMonkey. RESULTS 142 responses were received from 15 countries. The majority worked in academic institutions, had 5-20 years work-experience and irradiated <5 DCIS patients/year. PMRT was more given if: surgical margins <1 mm, high-grade, multicentricity, young age, tumour size >5 cm, skin- or nipple- sparing mastectomy. Moderate hypofractionation was the most common schedule, except after immediate breast reconstruction (57% conventional fractionation). CONCLUSIONS The present survey highlighted risk factors for PMRT administration, which should be further evaluated.
Collapse
Affiliation(s)
- A Montero-Luis
- Radiation Oncology, University Hospital HM Sanchinarro, Madrid, Spain.
| | - C Aristei
- Radiation Oncology, University of Perugia and Perugia General Hospital, Perugia, Italy
| | - I Meattini
- Radiation Oncology, Azienda Ospedaliero-Universitaria Careggi (AOUC), Florence, Italy
| | - M Arenas
- Radiation Oncology, University Hospital Sant Joan, Reus, Spain
| | - L Boersma
- Radiation Oncology, The Netherlands Cancer Institute, Antoni van Leeuwenhøek Huis, Amsterdam, Netherlands
| | - C Bourgier
- Radiation Oncology, ICM-Val d'Aurelle, Univ Montpellier, Montpellier, France
| | - C Coles
- Radiation Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
| | - B Cutuli
- Radiation Oncology, Institut du Cancer Courlancy, Reims, France
| | - L Falcinelli
- Radiation Oncology, Perugia General Hospital, Italy
| | - O Kaidar-Person
- Radiation Oncology Unit, Oncology Institute, Rambam Medical Center, Haifa, Israel
| | - M C Leonardi
- Radiation Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy
| | - B Offersen
- Radiation Oncology, Aarhus University Hospital, Aarhus, Denmark
| | - F Marazzi
- Radiation Oncology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy
| | - S Rivera
- Radiation Oncology, Institut Gustave Roussy, Villejuif, France
| | - L Tagliaferri
- Radiation Oncology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy
| | - V Tombolini
- Radiation Oncology, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy
| | - C Vidali
- Radiation Oncology, Azienda Sanitaria Universitaria Integrata di Trieste (ASUITS), Trieste, Italy
| | - V Valentini
- Radiation Oncology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy
| | - P Poortmans
- Radiation Oncology, Institut Curie, Department of Radiation Oncology; Paris Sciences & Lettres - PSL University; Paris, France
| |
Collapse
|
14
|
Saldi S, Perrucci E, Lancellotta V, Palumbo I, Falcinelli L, Mariucci C, Chierchini S, Bini V, Aristei C. EP-1292 Zinc-L-Carnosine prevents dysphagia in breast cancer patients treated with adjuvant radiotherapy. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)31712-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
15
|
Stick L, Lorenzen E, Yates E, Anandadas C, Andersen K, Aristei C, Byrne O, Hoi S, Jensen I, Kirby A, Kirova Y, Marrazzo L, Matías-Pérez A, Nielsen M, Nissen H, Oliveros S, Verhoeven K, Vikström J, Offersen B. PV-0046 Patient selection for proton therapy of early breast cancer - the DBCG phase II study strategy. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)30466-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
16
|
Iacco M, Zucchetti C, Dipilato A, Lupattelli M, Podlesko A, Fulcheri C, Marcantonini M, Reggioli V, Aristei C, Tarducci R. 179. Whole brain radiotherapy with hippocampal sparing and Simultaneous Integrated Boost for patients with one to four metastases with Helical Tomotherapy. Phys Med 2018. [DOI: 10.1016/j.ejmp.2018.04.190] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
17
|
Iacco M, Zucchetti C, Lupattelli M, Aristei C, Tarducci R. 182. Study of the accuracy of non-invasive fixation frames in brain treatments with Helical Tomotherapy. Phys Med 2018. [DOI: 10.1016/j.ejmp.2018.04.193] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
18
|
Chiesa S, Bartoli FB, Longo S, Lupattelli M, Gatta R, Palumbo I, Balducci M, Tarducci R, Cusumano D, Masciocchi C, Lenkowicz J, Russo R, Floridi P, Dinapoli N, Valentini V, Aristei C. Delta Radiomics Features Analysis for the Prediction of Patients Outcomes in Glioblastoma Multiforme: The Generating Hypothesis Phase of GLI.F.A. Project. Int J Radiat Oncol Biol Phys 2018. [DOI: 10.1016/j.ijrobp.2018.07.128] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
19
|
Lupattelli M, Chiesa S, Beghella Bartoli F, Palumbo I, Gatta R, Tarducci R, Dinapoli N, Balducci M, Aristei C, Valentini V. P04.90 Observational prospective multi-centric study of delta radiomics Features Analysis for the prediction of patients outcomes in GLIoblastoma multifome: GLI.F.A. Project. Neuro Oncol 2018. [DOI: 10.1093/neuonc/noy139.324] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- M Lupattelli
- Sezione di Radioterapia Oncologica, Dipartimento di Chirurgia e Scienze Biomedicali, Università di Perugia, Ospedale S. Maria della Misericordia, Perugia, Italy
| | - S Chiesa
- Fondazione Policlinico A. Gemelli IRCSS - Università Cattolica del Sacro Cuore, Dipartimento Scienze Radiologiche, Radioterapiche ed Ematologiche, Istituto di Radiologia, Rome, Italy
| | - F Beghella Bartoli
- Fondazione Policlinico A. Gemelli IRCSS - Università Cattolica del Sacro Cuore, Dipartimento Scienze Radiologiche, Radioterapiche ed Ematologiche, Istituto di Radiologia, Rome, Italy
| | - I Palumbo
- Sezione di Radioterapia Oncologica, Dipartimento di Chirurgia e Scienze Biomedicali, Università di Perugia, Ospedale S. Maria della Misericordia, Perugia, Italy
| | - R Gatta
- Fondazione Policlinico A. Gemelli IRCSS - Università Cattolica del Sacro Cuore, Dipartimento Scienze Radiologiche, Radioterapiche ed Ematologiche, Istituto di Radiologia, Rome, Italy
| | - R Tarducci
- Sezione di Radioterapia Oncologica, Dipartimento di Chirurgia e Scienze Biomedicali, Università di Perugia, Ospedale S. Maria della Misericordia, Perugia, Italy
| | - N Dinapoli
- Fondazione Policlinico A. Gemelli IRCCS, Dipartimento Scienze Radiologiche, Radioterapiche ed Ematologiche, Istituto di Radiologia, Roma, Italia, Rome, Italy
| | - M Balducci
- Fondazione Policlinico A. Gemelli IRCSS - Università Cattolica del Sacro Cuore, Dipartimento Scienze Radiologiche, Radioterapiche ed Ematologiche, Istituto di Radiologia, Rome, Italy
| | - C Aristei
- Sezione di Radioterapia Oncologica, Dipartimento di Chirurgia e Scienze Biomedicali, Università di Perugia, Ospedale S. Maria della Misericordia, Perugia, Italy
| | - V Valentini
- Fondazione Policlinico A. Gemelli IRCSS - Università Cattolica del Sacro Cuore, Dipartimento Scienze Radiologiche, Radioterapiche ed Ematologiche, Istituto di Radiologia, Rome, Italy
| |
Collapse
|
20
|
Amichetti M, Caffo O, Richetti A, Zini G, Rigon A, Antonello M, Roncadin M, Coghetto F, Valdagni R, Fasan S, Maluta S, Di Marco A, Neri S, Vidali C, Panizzoni G, Aristei C. Subclinical Ductal Carcinoma in Situ of the Breast: Treatment with Conservative Surgery and Radiotherapy. Tumori 2018; 85:488-93. [PMID: 10774571 DOI: 10.1177/030089169908500612] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Aims and Background In spite of the fact that ductal carcinoma in situ (DCIS) of the breast is a frequently encountered clinical problem, there is no consensus about the optimal treatment of clinically occult (i.e., mammographic presentation only) DCIS. Interest in breast conservation therapy has recently increased. Few data are available in Italy on the conservative treatment with surgery and adjuvant postoperative radiotherapy. Methods A retrospective multi-institutional study was performed in 15 Radiation Oncology Departments in northern Italy involving 112 women with subclinical DCIS of the breast treated between 1982 and 1993. Age of the patients ranged between 32 and 72 years (median, 50 years). All of them underwent conservative surgery: quadrantectomy in 89, tumorectomy in 11, and wide excision in 12 cases. The most common histologic subtype was comedocarcinoma (37%). The median pathologic size was 10 mm (range 1 to 55 mm). Axillary dissection was performed in 83 cases: all the patients were node negative. All the patients received adjunctive radiation therapy with 60Co units (77%) or 6 MV linear accelerators (23%) for a median total dose to the entire breast of 50 Gy (mean, 49.48 Gy; range, 45-60 Gy). Seventy-six cases (68%) received a boost to the tumor bed at a dose of 8-20 Gy (median 10 Gy) for a minimum tumor dose of 58 Gy. Results At a median follow-up of 66 months, 8 local recurrences were observed, 4 intraductal and 4 invasive. All recurrent patients had a salvage mastectomy and are alive and free of disease at this writing. The 10-year actuarial overall, cause-specific, and recurrence-free survival was of 98.8%, 100%, and 91%, respectively. Conclusions The retrospective multicentric study, with a local control rate of more than 90% at 10 years with 100% cause-specific survival, showed that conservative surgery and adjuvant radiation therapy is a safe and efficacious treatment for patients with occult, non-palpable DCIS.
Collapse
Affiliation(s)
- M Amichetti
- Radiation Oncology Department, Santa Chiara Hospital, Trento, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Ciatto S, Rosselli Del Turco M, Pacini P, Mustacchi G, Simonis M, Sismondi P, Giardina G, Belsanti V, Aristei C, Molino AM. Early Detection of Breast Cancer Recurrences through Periodic follow-up - is it Useless? Tumori 2018; 71:325-9. [PMID: 4049534 DOI: 10.1177/030089168507100402] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
The authors report on a multicentric consecutive series of 1120 breast cancer first recurrences. Cases detected as subjectively asymptomatic thanks to periodic follow-up examinations are compared to cases detected as symptomatic. The relapse-free interval from primary treatment was shorter for asymptomatic recurrences, confirming that an earlier diagnosis was achieved in these cases. In spite of this diagnostic anticipation, median and actuarial survival from primary treatment did not differ when asymptomatic recurrences were compared to symptomatic recurrences. The study results did not show any prognostic impact of periodic follow-up in breast cancer and urge for prospective controlled studies on this diffuse and expensive practice.
Collapse
|
22
|
Aristei C, Latini P, Faicinelli F, Latini RA, Aversa F. The Role of Total Body Irradiation in the Conditioning of Patients Receiving Haploidentical Stem Cell Transplantation. Tumori 2018; 87:402-6. [PMID: 11989595 DOI: 10.1177/030089160108700610] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Background Nearly 40% of patients requiring a hematopoietic stem cell transplant lack a suitable donor. However, virtually all these patients have a potential family donor with whom they share one HLA haplotype. Methods We report the rationale for making hematopoietic stem cell transplantation from haploidentical related donors feasible, as well as the method followed to achieve this. Two studies are reported, designed to overcome the problem of rejection and graft-versus-host disease after haploidentical stem cell transplantation. We describe how our total body irradiation-based, highly immuno- and myelosuppressive conditioning regimens were developed and how they have been modified over the years in an attempt to improve the clinical outcome of high-risk acute leukemia patients receiving large numbers of extensively T-cell-depleted hematopoietic stem cell transplantations from full-haplotype mismatched family donors. Results A high engraftment rate and an extremely low incidence of graft-versus-host disease were obtained. Modifications of the pretransplant schedules allowed the reduction of transplant-related toxicity. Conclusions The main obstacles that limited the use of haploidentical stem cell transplantation have been overcome. The procedure is now a reality that should be recommended in high-risk acute leukemia patients who do not have a suitable matched donor.
Collapse
Affiliation(s)
- C Aristei
- Institute of Radiotherapy Oncology, Perugia General Hospital and University, Italy.
| | | | | | | | | |
Collapse
|
23
|
Meattini I, Pasinetti N, Meduri B, De Rose F, De Santis M, Lancellotta V, Rossi F, Franco P, Alongi F, Saieva C, Olmetto E, Desideri I, D'Angelo E, Triggiani L, Ricardi U, Bastiani P, Aristei C, Lozza L, Scorsetti M, Livi L. OC-0160: DCIS treated with breast conservative surgery and radiotherapy: a national multicentre experience. Radiother Oncol 2018. [DOI: 10.1016/s0167-8140(18)30470-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
24
|
Saldi S, Chierchini S, Mendichi M, Lancellotta V, Bellavita R, Palumbo I, Dipilato T, Bini V, Aristei C. EP-1594: Analysis of urinary toxicity by uroflowmetry in hypofractionated radiotherapy after prostatectomy. Radiother Oncol 2018. [DOI: 10.1016/s0167-8140(18)31903-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
25
|
Meattini I, Pasinetti N, Meduri B, De Rose F, De Santis M, Lancellotta V, Rossi F, Franco P, Alongi F, Saieva C, Delli Paoli C, Desideri I, D’angelo E, Triggiani L, Ricardi U, Bastiani P, Aristei C, Lozza L, Scorsetti M, Livi L. Ductal carcinoma in situ treated with breast conservative surgery and radiotherapy: A national multicentre experience. Eur J Cancer 2018. [DOI: 10.1016/s0959-8049(18)30392-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
26
|
Iacco M, Saldi S, Zucchetti C, Dipilato A, Lancellotta V, Aristei C, Tarducci R. EP-1961: Classical Kaposi’s sarcoma treatment with helical tomotherapy: impact of polyurethane foam cushion. Radiother Oncol 2018. [DOI: 10.1016/s0167-8140(18)32270-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
27
|
Palazzari E, Lupattelli M, Galuppo C, Napoletano M, Podlesko A, Bini V, Iacco M, Fulcheri C, Verzini G, De Paoli A, Aristei C. PO-1065: Role of CT-MRI co-registration in tumor delineation for preoperative radiotherapy of rectal cancer. Radiother Oncol 2018. [DOI: 10.1016/s0167-8140(18)31375-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
28
|
Kirova Y, Carroll S, Fourquet A, Offersen B, Aristei C, Chen JY. The St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology. Ann Oncol 2018; 29:280-281. [DOI: 10.1093/annonc/mdx537] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
29
|
Iacco M, Zucchetti C, Lupattelli M, Aristei C, Fulcheri C, Tarducci R. EP-1578: Frameless intracranial radiosurgery with Helical Tomotherapy: preliminary results. Radiother Oncol 2017. [DOI: 10.1016/s0167-8140(17)32013-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
30
|
Lancellotta V, Iacco M, Chierchini S, Perrucci E, Palumbo I, Falcinelli L, Saccia S, Nucciarelli S, Milletti A, Aristei C. EP-1176: Helical tomotherapy in chest wall/breast and draining node irradiation after breast cancer surgery. Radiother Oncol 2017. [DOI: 10.1016/s0167-8140(17)31612-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
31
|
Perrucci E, Montesi G, Marcantonini M, Mariucci C, Mendichi M, Saccia S, Cavalli A, Didona A, Lancellotta V, Bini V, Aristei C. EP-1527: Pelvic Intensity-Modulated Radiotherapy in prone and supine position in gynaecological cancer. Radiother Oncol 2017. [DOI: 10.1016/s0167-8140(17)31962-x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
32
|
Iacco M, Zucchetti C, Lupattelli M, Dipilato A, Aristei C, Tarducci R. EP-1636: Evaluation of the accuracy in frame-less image-guided radiotherapy and radiosurgery. Radiother Oncol 2017. [DOI: 10.1016/s0167-8140(17)32071-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
33
|
Lancellotta V, Tini A, Saccia S, Trinari S, Dazzini S, Verzini G, Mearelli N, Bini V, Cavalli A, Perrucci E, Aristei C. EP-1817: Breast set-up: Assessing two immobilization systems. Radiother Oncol 2017. [DOI: 10.1016/s0167-8140(17)32180-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
34
|
Mariucci C, Podlesko A, Perrucci E, Falcinelli L, Bini V, Di Benedetto M, Arena E, Nucciarelli S, Lancellotta V, Palumbo I, Aristei C. EP-1189: Hypofractionated RT with or without boost in breast cancer: an institutional analysis of toxicity. Radiother Oncol 2016. [DOI: 10.1016/s0167-8140(16)32439-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
35
|
Didona A, Zucchetti C, Dipilato A, Iacco M, Panizza M, Frattegiani A, Bini V, Aristei C, Tarducci R. EP-1693: Constant dose rate VMAT and step-and-shoot IMRT in head and neck cancer: a comparative plan analysis. Radiother Oncol 2016. [DOI: 10.1016/s0167-8140(16)32944-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
36
|
Marcantonini M, Lancellotta V, Montesi G, Falcinelli L, Aristei C, Tarducci R. Protocol implementation of total marrow irradiation (TMI) plus total lymphoid irradiation (TLI) using helical tomotherapy (HT). Phys Med 2016. [DOI: 10.1016/j.ejmp.2016.01.141] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
37
|
Didona A, Zucchetti C, Aristei C, Tarducci R. Volumetric modulated arc therapy for delivery of head and neck radiotherapy: Comparison between constant and variable dose rate. Phys Med 2016. [DOI: 10.1016/j.ejmp.2016.01.070] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
38
|
Iacco M, Zucchetti C, Marcantonini M, Dipilato A, Lancellotta V, Aristei C, Tarducci R. Dosimetric comparison between four irradiation techniques for breast cancer. Phys Med 2016. [DOI: 10.1016/j.ejmp.2016.01.112] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
39
|
Stracci F, Bianconi F, Leite S, Liso A, La Rosa F, Lancellotta V, van de Velde CJH, Aristei C. Linking surgical specimen length and examined lymph nodes in colorectal cancer patients. Eur J Surg Oncol 2015; 42:260-5. [PMID: 26723169 DOI: 10.1016/j.ejso.2015.11.017] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2015] [Revised: 10/28/2015] [Accepted: 11/20/2015] [Indexed: 12/18/2022] Open
Abstract
AIM The number of examined lymph nodes (NLN) was associated with survival of stages II and III colorectal cancer (CRC) patients. Guidelines recommend examining at least 12 lymph nodes. This study investigated the influence of surgical specimen length on lymph node harvest and compliance with international guidelines. MATERIALS AND METHODS This population-based study included 4,724 cases of surgically treated CRC that were diagnosed from 2002 to 2008. Multivariate analyses were performed for the main study variables (age, gender, diagnosis at screening or in symptomatic patients, cancer site, staging, grading, number of positive nodes, neo-adjuvant treatment for rectal cancer, hospital were surgery was performed). Fractional polynomial models investigated the relationship between continuous variables and outcomes. RESULTS The NLN increased over time reaching ≥12 NLN in 64% of cases at the end of the study period. More NLN were associated with young age, right colon cancer, pT3-T4 disease, stages II and III and high grade. Fewer NLN were associated with short surgical specimen length and neo-adjuvant treatment in rectal cancer patients. Use of laparoscopy increased sharply over time. CONCLUSIONS NLN increased over time in accordance with international guidelines. Surgical specimen length correlated with NLN which may determine therapeutic choices, particularly in stage II colon cancer. When harvested lymph nodes are under 10 in number and all are negative, chemotherapy is always recommended. As specimen lengths <20 cm were associated with a high risk of inadequate NLN counts, patients are at risk of over-treatment.
Collapse
Affiliation(s)
- F Stracci
- Department of Experimental Medicine, Public Health Section, University of Perugia, Italy; Umbria Cancer Registry, Italy
| | - F Bianconi
- Department of Experimental Medicine, Public Health Section, University of Perugia, Italy; Umbria Cancer Registry, Italy
| | - S Leite
- Umbria Cancer Registry, Italy
| | - A Liso
- Department of Medicine and Surgery, University of Foggia, Italy
| | | | - V Lancellotta
- Department of Surgical and Biomedical Science, Radiation Oncology Section, University of Perugia, Italy
| | - C J H van de Velde
- Department of Surgery, Leiden University Medical Center, The Netherlands
| | - C Aristei
- Department of Surgical and Biomedical Science, Radiation Oncology Section, University of Perugia, Italy; Radiation Oncology, Perugia General Hospital, Italy.
| |
Collapse
|
40
|
Palumbo I, Palumbo B, Fravolini ML, Marcantonini M, Perrucci E, Latini ME, Falcinelli L, Sabalich I, Tranfaglia C, Schillaci G, Mannarino E, Aristei C. Brain natriuretic peptide as a cardiac marker of transient radiotherapy-related damage in left-sided breast cancer patients: A prospective study. Breast 2015; 25:45-50. [PMID: 26547836 DOI: 10.1016/j.breast.2015.10.004] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2015] [Revised: 09/04/2015] [Accepted: 10/10/2015] [Indexed: 10/22/2022] Open
Abstract
PURPOSE Our study evaluated brain natriuretic peptide (BNP) changes over time after adjuvant radiotherapy (RT) in women with left-sided breast cancer investigating its correlation with heart dosimetric parameters. METHODS Forty-three patients underwent clinical cardiac examination, electrocardiogram (ECG), echocardiography and BNP measurement before RT (T0) and 1 (T1), 6 (T6) and 12 months (T12) after. After T12 cardiac assessment was performed annually in each patient. Mean values and standard deviation (SD) of BNP, left ventricular ejection fraction (LVEF), V20, V25, V30, V45 and mean dose were calculated. Normalized BNP (BNPn) was calculated as follows: BNPnT1 = BNPT1/BNPT0, BNPnT6 = BNPT6/BNPT0, BNPnT12 = BNPT12/BNPT0. Absolute BNP and BNPn values were used for data analysis. RESULTS Median follow-up from the end of RT to the last check-up was 87 months (range 37-120 months). Minimum follow-up was 74 months except for two patients, who died at respectively 37 and 47 months after RT. In all patients LVEF did not change significantly (p = 0.22) after RT. BNP increased significantly (p < 0.001), particularly 1 and 6 months after RT. It slightly decreased after 12 months. BNP did not correlate with V20, V25, V30, V45, mean dose and MHD. All BNPn correlated significantly (p < 0.05) with V20, V25, V30, V45, mean dose and MHD. Four patients had a cardiac event; in the only subject who developed myocardial infarction, V20, V25, V30 and V45 were the highest and BNP increased from T1 and persisted high even at T12. CONCLUSION Our results confirm that BNP could be a useful minimally invasive marker of early RT related cardiac impairment.
Collapse
Affiliation(s)
- I Palumbo
- Radiation Oncology Section, University of Perugia, Perugia General Hospital, Perugia, Italy.
| | - B Palumbo
- Nuclear Medicine and Health Physics Section, University of Perugia, Perugia, Italy
| | - M L Fravolini
- Department of Engineering, University of Perugia, Italy
| | - M Marcantonini
- Medical Physics Unit, Perugia General Hospital, Perugia, Italy
| | - E Perrucci
- Radiation Oncology Division, Perugia General Hospital, Perugia, Italy
| | - M E Latini
- Radiology Division, Perugia General Hospital, Perugia, Italy
| | - L Falcinelli
- Radiation Oncology Division, Perugia General Hospital, Perugia, Italy
| | - I Sabalich
- Nuclear Medicine and Health Physics Section, University of Perugia, Perugia, Italy
| | - C Tranfaglia
- Nuclear Medicine and Health Physics Section, University of Perugia, Perugia, Italy
| | - G Schillaci
- Internal Medicine Unit, Department of Medicine, University of Perugia, Italy
| | - E Mannarino
- Internal Medicine, Angiology and Arteriosclerosis Diseases Unit, Department of Medicine, University of Perugia, Italy
| | - C Aristei
- Radiation Oncology Section, University of Perugia, Perugia General Hospital, Perugia, Italy
| |
Collapse
|
41
|
Di Benedetto M, Lupattelli M, Lancellotta V, Palazzari E, Tini A, Salari B, Mearelli N, Corgna E, Aristei C. EP-1683: Palliative radiotherapy in unfit locally advanced or metastatic rectal cancer patients. Radiother Oncol 2015. [DOI: 10.1016/s0167-8140(15)41675-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
42
|
Palazzari E, Amico L, Santucci A, Carotti A, Perrucci E, Cavalli A, Velardi A, Aristei C. EP-1352: TBI scheme impacted on relapse in acute myeloid leukemia patients after hematopoietic stem cell transplant. Radiother Oncol 2015. [DOI: 10.1016/s0167-8140(15)41344-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
43
|
Lancellotta V, Chirico L, Palumbo I, Anselmo P, Zucchetti C, Italiani M, Bini V, Maranzano E, Aristei C. OC-0041: PBI with interstitial high-dose-rate brachytherapy: results of a phase II prospective study. Radiother Oncol 2015. [DOI: 10.1016/s0167-8140(15)40041-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
44
|
Arcidiacono F, Bellavita R, Falcinelli L, Saldi S, Matrone F, Mendichi M, Salari B, Bini V, Aristei C. PO-0676: Dosimetric predictive factors for radiation pneumonitis in sterotactic body radiotherapy. Radiother Oncol 2015. [DOI: 10.1016/s0167-8140(15)40668-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
45
|
Bellavita R, Mariucci C, Lupattelli M, Matrone F, Didona A, Mendichi M, Cecchetti S, Russo S, Zucchetti C, Aristei C. EP-1251: Prostate cancer reirradiation with Helical Tomotherapy. Radiother Oncol 2015. [DOI: 10.1016/s0167-8140(15)41243-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
46
|
Saldi S, Arcidiacono F, Bellavita R, Baffa N, Falcinelli L, Montesi G, Arena E, Porcari M, Paglione F, Bini V, Aristei C. EP-1182: FDG-PET does not predict outcome for early stage nonsmall- cell lung cancer after sterotactic body radiotherapy. Radiother Oncol 2015. [DOI: 10.1016/s0167-8140(15)41174-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
47
|
Lupattelli M, Lancellotta V, Mosca S, Fischer M, Russo G, Saccia S, Pallottini S, Aristei C. EP-1614: High dose-rate intraluminal brachytherapy as palliative treatment of malignant obstructive jaundice. Radiother Oncol 2015. [DOI: 10.1016/s0167-8140(15)41606-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
48
|
Perrucci E, Lancellotta V, Bini V, Mariucci C, Di Benedetto M, Trinari S, Verzini S, Aristei C. PO-1020: High-dose rate vaginal brachytherapy in early stage endometrial cancer. Radiother Oncol 2015. [DOI: 10.1016/s0167-8140(15)41012-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
49
|
Matrone F, Montesi G, Saldi S, Bellavita R, Frattegiani A, Lupattelli M, Zucchetti C, Cusco S, Bini V, Aristei C. EP-1260: Risk factors for acute toxicity in prostate cancer patients receiving hypofractionated IMRT. Radiother Oncol 2015. [DOI: 10.1016/s0167-8140(15)41252-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
50
|
Antognelli C, Palumbo I, Aristei C, Talesa VN. Glyoxalase I inhibition induces apoptosis in irradiated MCF-7 cells via a novel mechanism involving Hsp27, p53 and NF-κB. Br J Cancer 2014; 111:395-406. [PMID: 24918814 PMCID: PMC4102940 DOI: 10.1038/bjc.2014.280] [Citation(s) in RCA: 46] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2014] [Revised: 04/24/2014] [Accepted: 04/30/2014] [Indexed: 01/07/2023] Open
Abstract
BACKGROUND Glyoxalase I (GI) is a cellular defence enzyme involved in the detoxification of methylglyoxal (MG), a cytotoxic byproduct of glycolysis, and MG-derived advanced glycation end products (AGEs). Argpyrimidine (AP), one of the major AGEs coming from MG modifications of proteins arginines, is a pro-apoptotic agent. Radiotherapy is an important modality widely used in cancer treatment. Exposure of cells to ionising radiation (IR) results in a number of complex biological responses, including apoptosis. The present study was aimed at investigating whether, and through which mechanism, GI was involved in IR-induced apoptosis. METHODS Apoptosis, by TUNEL assay, transcript and protein levels or enzymatic activity, by RT-PCR, western blot and spectrophotometric methods, respectively, were evaluated in irradiated MCF-7 breast cancer cells, also in experiments with appropriate inhibitors or using small interfering RNA. RESULTS Ionising radiation induced a dramatic reactive oxygen species (ROS)-mediated inhibition of GI, leading to AP-modified Hsp27 protein accumulation that, in a mechanism involving p53 and NF-κB, triggered an apoptotic mitochondrial pathway. Inhibition of GI occurred at both functional and transcriptional levels, the latter occurring via ERK1/2 MAPK and ERα modulation. CONCLUSIONS Glyoxalase I is involved in the IR-induced MCF-7 cell mitochondrial apoptotic pathway via a novel mechanism involving Hsp27, p53 and NF-κB.
Collapse
Affiliation(s)
- C Antognelli
- Department of Experimental Medicine, University of Perugia, Sant'Andrea delle Fratte, 06132 Perugia, Italy
| | - I Palumbo
- Radiation Oncology Section, University of Perugia, Sant'Andrea delle Fratte, 06132 Perugia, Italy
| | - C Aristei
- Radiation Oncology Section, University of Perugia, Sant'Andrea delle Fratte, 06132 Perugia, Italy
| | - V N Talesa
- Department of Experimental Medicine, University of Perugia, Sant'Andrea delle Fratte, 06132 Perugia, Italy
| |
Collapse
|